Publications by authors named "D Donald"
Article Synopsis
- Hypopituitarism is a disorder marked by low levels of one or more anterior pituitary hormones, with notable differences in health outcomes between sexes; women experience higher rates of cardiovascular issues and higher mortality.
- The dysfunction of the hypothalamic-pituitary-gonadal (HPG) axis leads to hormonal deficiencies (like estrogen and testosterone), and treating these deficiencies with hormone replacement therapy is crucial for health benefits.
- Despite the positive effects of hormone replacement in reducing mortality risk, the reasons behind the sex disparities in health outcomes for hypopituitarism patients remain unclear, with possibilities including lack of aggressive treatment for women and premature loss of protective estrogen effects.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFCoastal ecosystems dominate oceanic methane (CH4) emissions. However, there is limited knowledge about how biotic interactions between infauna and aerobic methanotrophs (i.e.
View Article and Find Full Text PDFHyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer.
Endocr Oncol
January 2022
Hyponatraemia is a common electrolyte abnormality seen in a wide range of oncological and haematological malignancies and confers poor performance status, prolonged hospital admission and reduced overall survival, in patients with cancer. Syndrome of inappropriate antidiuresis (SIAD) is the commonest cause of hyponatraemia in malignancy and is characterised by clinical euvolaemia, low plasma osmolality and concentrated urine, with normal renal, adrenal and thyroid function. Causes of SIAD include ectopic production of vasopressin (AVP) from an underlying tumour, cancer treatments, nausea and pain.
View Article and Find Full Text PDFBackground: Nearly 40% of patients do not continue proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy after 6 months, despite their ability to lower low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events. Limited work has assessed persistence to PCSK9i therapy in an integrated specialty pharmacy model.
Objective: To assess rates of persistence to PCSK9i therapy and report reasons for non-persistence in patients serviced within an integrated specialty pharmacy.